CenExel iResearch, LLC

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Source

• Not yet recruiting

  A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

  NCT07881887· Phase 1· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Source

• Recruiting

  A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

  NCT07734493· Phase 1· Source

• Recruiting

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Phase 3· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

  NCT07565428· Phase 3· Source

• Recruiting

  A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07481630· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

  NCT07061288· Phase 1· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

  NCT06951711· Phase 3· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

  NCT06808984· Phase 2· Source

• Active, not recruiting

  PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

  NCT06750432· Phase 1· Source

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Source

• Active, not recruiting

  Psilocybin for Major Depressive Disorder (MDD)

  NCT06308653· Phase 3· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

  NCT06075667· Phase 3· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression3 recruiting
• Schizophrenia3 recruiting
• Alzheimer disease2 recruiting
• Bipolar disorder2 recruiting
• Migraine2 recruiting
• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoarthritis1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

  NCT06973720· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

  NCT06897202· Phase 2· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Source

• Terminated

  BHV-7000 Open-Label Extension Bipolar Mania Study

  NCT06423794· Phase 2· Source

• Completed

  BHV-7000 Acute Treatment of Bipolar Mania

  NCT06419582· Phase 2/3· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Source

• Completed

  Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

  NCT06126497· Phase 2· Source

• Completed

  A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

  NCT05686044· Phase 2/3· Source

• Completed

  A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

  NCT05357989· Phase 3· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Source